Fundamentals Overview
Abbott Laboratories is in the middle of its 52-week range with premium valuation, trading relatively flat today.
Valuation premium
Intrinsic value (DCF)
+34.4% upside vs price
Profitability
Risk (Beta)
0.58 — lower vol
Earnings & growth
BullzEye Analysis
Our composite tilts Buy on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
DCF +34.4% upside vs price · Analyst grade: B+ · Sentiment improving (1 upgrade) · 3M vs S&P 500: +25.7% · 3M vs Healthcare sector: +13%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 13, Outperform: 8, Overweight: 9.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $147.50; current price is $109.74. That’s a +34.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 35.26 |
| DCF value (model) | $147.50 (34.4% upside) |
| PEG (TTM) | N/A |
| P/B (TTM) | 3.74 |
| P/S (TTM) | 4.08 |
| P/FCF (TTM) | 21.78 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 1.38 |
| Quick Ratio (TTM) | 0.97 |
| Cash Ratio (TTM) | 0.29 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 11.65% |
| Gross margin (TTM) | 56.8% |
| Operating margin (TTM) | 17.03% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for ABT.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| UBS | maintain | Buy | Buy | 2026-07-28 |
| RBC Capital | maintain | Outperform | Outperform | 2026-07-17 |
| TD Cowen | maintain | Buy | Buy | 2026-07-17 |
| Citigroup | maintain | Buy | Buy | 2026-07-17 |
| BTIG | maintain | Buy | Buy | 2026-07-17 |
| JP Morgan | maintain | Overweight | Overweight | 2026-07-17 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-07-17 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-07-17 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-07-17 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-07-06 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-06-22 |
| BTIG | maintain | Buy | Buy | 2026-04-27 |
| Barclays | maintain | Overweight | Overweight | 2026-04-20 |
| Oppenheimer | maintain | Outperform | Outperform | 2026-04-17 |
| Stifel | maintain | Buy | Buy | 2026-04-17 |
| Benchmark | maintain | Buy | Buy | 2026-04-17 |
| BTIG | maintain | Buy | Buy | 2026-04-17 |
| B of A Securities | maintain | Buy | Buy | 2026-04-17 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-04-17 |
| RBC Capital | maintain | Outperform | Outperform | 2026-04-17 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-04-17 |
| Goldman Sachs | maintain | Buy | Buy | 2026-04-09 |
| Barclays | maintain | Overweight | Overweight | 2026-04-08 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-04-06 |
| BTIG | maintain | Buy | Buy | 2026-03-31 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-03-26 |
| Citigroup | maintain | Buy | Buy | 2026-03-11 |
| Barclays | maintain | Overweight | Overweight | 2026-02-02 |
| Freedom Broker | upgrade | Hold | Buy | 2026-01-29 |
| Evercore ISI Group | maintain | Outperform | Outperform | 2026-01-23 |